Department of Emergency Medicine, University of California, Davis.
Department of Emergency Medicine, University of California, San Francisco.
JAMA Netw Open. 2024 Aug 1;7(8):e2429154. doi: 10.1001/jamanetworkopen.2024.29154.
The incidence of opioid-associated out-of-hospital cardiac arrest (OA-OHCA) has grown from less than 1% of OHCA in 2000 to between 7% and 14% of OHCA in recent years; American Heart Association (AHA) protocols suggest that emergency medical service (EMS) clinicians consider naloxone in OA-OHCA. However, it is unknown whether naloxone improves survival in these patients or in patients with undifferentiated OHCA.
To evaluate the association of naloxone with clinical outcomes in patients with undifferentiated OHCA.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of EMS-treated patients aged 18 or older who received EMS treatment for nontraumatic OHCA in 3 Northern California counties between 2015 and 2023. Data were analyzed using propensity score-based models from February to April 2024.
EMS administration of naloxone.
The primary outcome was survival to hospital discharge; the secondary outcome was sustained return of spontaneous circulation (ROSC). Covariates included patient and cardiac arrest characteristics (eg, age, sex, nonshockable rhythm, any comorbidity, unwitnessed arrest, and EMS agency) and EMS clinician determination of OHCA cause as presumed drug-related.
Among 8195 patients (median [IQR] age, 65 [51-78] years; 5540 male [67.6%]; 1304 Asian, Native Hawaiian, or Pacific Islander [15.9%]; 1119 Black [13.7%]; 2538 White [31.0%]) with OHCA treated by 5 EMS agencies from 2015 to 2023, 715 (8.7%) were believed by treating clinicians to have drug-related OHCA. Naloxone was administered to 1165 patients (14.2%) and was associated with increased ROSC using both nearest neighbor propensity matching (absolute risk difference [ARD], 15.2%; 95% CI, 9.9%-20.6%) and inverse propensity-weighted regression adjustment (ARD, 11.8%; 95% CI, 7.3%-16.4%). Naloxone was also associated with increased survival to hospital discharge using both nearest neighbor propensity matching (ARD, 6.2%; 95% CI, 2.3%-10.0%) and inverse propensity-weighted regression adjustment (ARD, 3.9%; 95% CI, 1.1%-6.7%). The number needed to treat with naloxone was 9 for ROSC and 26 for survival to hospital discharge. In a regression model that assessed effect modification between naloxone and presumed drug-related OHCA, naloxone was associated with improved survival to hospital discharge in both the presumed drug-related OHCA (odds ratio [OR], 2.48; 95% CI, 1.34-4.58) and non-drug-related OHCA groups (OR, 1.35; 95% CI, 1.04-1.77).
In this retrospective cohort study, naloxone administration as part of EMS management of OHCA was associated with increased rates of ROSC and increased survival to hospital discharge when evaluated using propensity score-based models. Given the lack of clinical practice data on the efficacy of naloxone in OA-OHCA and OHCA in general, these findings support further evaluation of naloxone as part of cardiac arrest care.
阿片类药物相关院外心脏骤停 (OA-OHCA) 的发生率从 2000 年的不到 OHCA 的 1%增长到近年来的 7%至 14%;美国心脏协会 (AHA) 方案建议,紧急医疗服务 (EMS) 临床医生在 OA-OHCA 中考虑使用纳洛酮。然而,尚不清楚纳洛酮是否能改善这些患者或未分化 OHCA 患者的生存。
评估纳洛酮与未分化 OHCA 患者临床结局的相关性。
设计、地点和参与者:这是一项回顾性队列研究,纳入了 2015 年至 2023 年期间在加利福尼亚州北部 3 个县接受 EMS 治疗的年龄在 18 岁或以上的非创伤性 OHCA 患者,这些患者接受了 EMS 治疗。数据使用 2024 年 2 月至 4 月的基于倾向评分的模型进行分析。
EMS 给予纳洛酮。
主要结局是存活至出院;次要结局是持续自主循环恢复 (ROSC)。协变量包括患者和心脏骤停特征(例如,年龄、性别、非电击节律、任何合并症、无人见证的骤停和 EMS 机构)和 EMS 临床医生对 OHCA 原因的判断,如假定与药物相关。
在 2015 年至 2023 年期间,由 5 个 EMS 机构治疗的 8195 例(中位数 [IQR] 年龄,65 [51-78] 岁;5540 例男性 [67.6%];1304 例亚洲人、夏威夷原住民或太平洋岛民 [15.9%];1119 例黑人 [13.7%];2538 例白人 [31.0%])OHCA 患者中,有 715 例(8.7%)被治疗临床医生认为与药物相关。在使用最近邻倾向匹配(绝对风险差异 [ARD],15.2%;95%CI,9.9%-20.6%)和逆概率加权回归调整(ARD,11.8%;95%CI,7.3%-16.4%)时,纳洛酮被给予 1165 例患者,与 ROSC 相关,纳洛酮也与存活至出院相关,使用最近邻倾向匹配(ARD,6.2%;95%CI,2.3%-10.0%)和逆概率加权回归调整(ARD,3.9%;95%CI,1.1%-6.7%)。使用纳洛酮的治疗效果需要治疗人数为 9 例,以实现 ROSC,需要治疗人数为 26 例,以实现存活至出院。在评估纳洛酮与假定药物相关 OHCA 之间的效应修饰的回归模型中,纳洛酮与假定药物相关 OHCA(比值比 [OR],2.48;95%CI,1.34-4.58)和非药物相关 OHCA 组(OR,1.35;95%CI,1.04-1.77)的存活至出院相关。
在这项回顾性队列研究中,纳洛酮作为 EMS 管理 OHCA 的一部分,在使用倾向评分模型评估时,与 ROSC 发生率增加和存活至出院增加相关。鉴于 OA-OHCA 和一般 OHCA 中纳洛酮疗效的临床实践数据缺乏,这些发现支持进一步评估纳洛酮作为心脏骤停护理的一部分。